Human sVEGFR3/Flt-4 DuoSet ELISA

Name: Human sVEGFR3/Flt-4 DuoSet ELISA
Brand: R&D Systems
SKU: DY349
Rating: 5 (1 reviews)

Catalog # DY349 | R&D Systems, Inc. a Bio-Techne Brand

(1)

Citations (10)

Product Datasheet / COA / SDS

New Version Available - DY349B-05

Discontinued Product

DY349 has been discontinued and is replaced by DY349B-05.

Setting the standard in quality research reagents

Key Product Details

Assay Type:	Solid Phase Sandwich ELISA
Assay Range:	156 - 10,000 pg/mL
Sample Types:	Cell culture supernates, serum, and plasma Note: Diluents for complex matrices, such as serum and plasma, should be evaluated prior to use in this DuoSet
Human sVEGFR3/Flt-4 DuoSet ELISA Features:	Optimized capture and detection antibody pairings with recommended concentrations save lengthy development time Development protocols are provided to guide further assay optimization Assay can be customized to your specific needs Economical alternative to complete kits

View Full Technical Details for Human sVEGFR3/Flt-4 DuoSet ELISA

Summary for Human sVEGFR3/Flt-4 DuoSet ELISA

This DuoSet ELISA Development kit contains the basic components required for the development of sandwich ELISAs to measure natural and recombinant human sVEGF R3/Flt-4. The suggested diluent is suitable for the analysis of most cell culture supernate samples. Diluents for complex matrices, such as serum and plasma, should be evaluated prior to use in this DuoSet.

Product Specifications for Human sVEGFR3/Flt-4 DuoSet ELISA

Assay Format	96-well strip plate (sold separately)
Sample Volume Required	100 µL
Reactivity	Human
Specificity	Please see the product datasheet
Detection Method	Colorimetric ELISA - 450nm (TMB)
Conjugate	Biotin
Label	HRP
Measurement	Quantitative ELISA
Sufficient Materials	For fifteen 96-well plates*

* Provided that the recommended microplates, buffers, diluents, substrates and solutions are used, and the assay is run as summarized in the Assay Procedure provided.

Kit Contents for Human sVEGFR3/Flt-4 DuoSet ELISA

Capture Antibody
Detection Antibody
Recombinant Standard
Streptavidin conjugated to horseradish-peroxidase (Streptavidin-HRP)

Other Reagents Required

DuoSet Ancillary Reagent Kit 2 (5 plates): (Catalog # DY008) containing 96 well microplates, plate sealers, substrate solution, stop solution, plate coating buffer (PBS), wash buffer, and Reagent Diluent Concentrate 2.

The components listed above may be purchased separately:

PBS: (Catalog # DY006), or 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.2 - 7.4, 0.2 µm filtered

Wash Buffer: (Catalog # WA126), or 0.05% Tween® 20 in PBS, pH 7.2-7.4

Reagent Diluent: (Catalog # DY995), or 1% BSA in PBS, pH 7.2-7.4, 0.2 µm filtered

Substrate Solution: 1:1 mixture of Color Reagent A (H2O2) and Color Reagent B (Tetramethylbenzidine) (Catalog # DY999)

Stop Solution: 2 N H2SO4 (Catalog # DY994)

Microplates: R&D Systems (Catalog # DY990)

Plate Sealers: ELISA Plate Sealers (Catalog # DY992)

Scientific Data Examples for Human sVEGFR3/Flt-4 DuoSet ELISA

	Human VEGF R3 / Flt-4 ELISA Standard Curve

Preparation and Storage

Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: VEGFR3/Flt-4

VEGF R1 (Flt-1), VEGF R2 (KDR/Flk-1), and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domain and kinase insert domains in their intracellular region. They are best known for regulating VEGF family-mediated vasculogenesis, angiogenesis, and lymphangiogenesis. They are also mediators of neurotrophic activity and regulators of hematopoietic development. VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis.

Item	Value
Long Name	Vascular Endothelial Growth Factor Receptor 3
Entrez Gene IDs	2324 (Human); 14257 (Mouse)
Alternate Names	EC 2.7.10, EC 2.7.10.1, FLT4, Flt-4, LMPH1A, PCLFLT41, Tyrosine-protein kinase receptor FLT4, VEGF R3, VEGFR-3, VEGFR3, VEGFR3Fms-like tyrosine kinase 4, fms-related tyrosine kinase 4, soluble VEGFR3 variant 1, soluble VEGFR3 variant 2, soluble VEGFR3 variant 3, vascular endothelial growth factor receptor 3

Citations for Human sVEGFR3/Flt-4 DuoSet ELISA (10)

Showing 1 - 10 of 10 citations Showing All

Filter By:

Search Title:

Citations are publications that use Bio-Techne products. Selected citations for Human sVEGFR3/Flt-4 DuoSet ELISA include:

Species: Human
Sample Types: Plasma

Kumar N et al. (2016-10-04), Tuberculosis-diabetes co-morbidity is characterized by heightened systemic levels of circulating angiogenic factors. J Infect, 2016-174(1):10-21.
PMID: 27717783
Species: Human
Sample Types: Plasma

Kumar N et al. (2016-01-04), Circulating Angiogenic Factors as Biomarkers of Disease Severity and Bacterial Burden in Pulmonary Tuberculosis. PLoS ONE, 2016-011(1):e0146318.
PMID: 26727122
Species: Human
Sample Types: Cell Culture Supernates

Tabata T et al. (2012-09-07), Cytomegalovirus impairs cytotrophoblast-induced lymphangiogenesis and vascular remodeling in an in vivo human placentation model. Am J Pathol, 2012-0181(5):1540-59.
PMID: 22959908
Species: Human
Sample Types: Plasma

Llovet JM et al. (2012-02-28), Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin. Cancer Res., 2012-018(8):2290-300.
PMID: 22374331
Species: Human
Sample Types: Plasma

Harmon CS et al. (2011-07-25), Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. J Transl Med, 2011-09(0):120.
PMID: 21787417
Species: Human
Sample Types: Plasma

Sallinen H et al. (2008-12-02), Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice. Mol. Ther., 2008-117(2):278-84.
PMID: 19050699
Species: Human
Sample Types: Plasma

Rini BI et al. (2008-08-01), Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol., 2008-026(22):3743-8.
PMID: 18669461
Species: Human
Sample Types: Plasma

Burstein HJ et al. (2008-03-17), Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol., 2008-026(11):1810-6.
PMID: 18347007
Species: Human
Sample Types: Serum

Lee JH et al. (2007-12-20), Single-nucleotide polymorphisms and haplotypes in the VEGF receptor 3 gene and the haplotype GC in the VEGFA gene are associated with psoriasis in Koreans. J. Invest. Dermatol., 2007-1128(6):1599-603.
PMID: 18094729
Species: Human
Sample Types: Plasma

Saltz LB et al. (2007-10-20), Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J. Clin. Oncol., 2007-125(30):4793-9.
PMID: 17947727

There are no citations that match your criteria.

Showing 1 - 10 of 10 citations Showing All

Customer Reviews for Human sVEGFR3/Flt-4 DuoSet ELISA (1)

5 out of 5

1 customer rating

5 stars

100%

4 stars

3 stars

2 stars

1 star

Showing 1 - 1 of 1 review Showing All

Filter By:

Human VEGFR3/Flt-4 DuoSet ELISA

Name: Jenna Nguyen

Sample Tested: 4T1 mouse breast cancer cell line

Verified Customer | Posted 10/17/2019

There are no reviews that match your criteria.

Showing 1 - 1 of 1 review Showing All

Product Documents for Human sVEGFR3/Flt-4 DuoSet ELISA

Product Datasheets

Download Product Datasheets

COA

SDS

Download SDS